Tags

Type your tag names separated by a space and hit enter

Treatment Response To Osimertinib In EGFR-Mutated Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Series.
Onco Targets Ther. 2019; 12:7785-7790.OT

Abstract

Therapy for leptomeningeal metastases (LM) from non-small cell lung cancer (NSCLC) is challenging, and conventional treatments have little impact on the disease course. We report three cases that were definitively diagnosed as LM from NSCLC with a mutation of epidermal growth factor receptor (EGFR) L858R. The systemic therapies of chemotherapy, local radiotherapy, and early generation tyrosine kinase inhibitors (TKIs) were implemented but ineffective. Three patients were treated with the third-generation TKI osimertinib at 80 mg daily, despite their different detection levels of T790M in the cerebrospinal fluid (CSF) and plasma, and achieved symptomatic remission, a decline of carcinoembryonic antigen (CEA) levels, and stable lesions. After the progression of LM, osimertinib at 160 mg daily further lengthened the quality of life and survival time of patients without any notable side effects during treatment. Recent related studies and our cases indicate that osimertinib has a positive effect on LM from EGFR-mutant NSCLC, regardless of T790M status.

Authors+Show Affiliations

Department of Geriatric Oncology, Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, People's Republic of China.Department of Geriatric Oncology, Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, People's Republic of China.Department of Geriatric Oncology, Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, People's Republic of China.Department of Geriatric Oncology, Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, People's Republic of China.The Comprehensive Cancer Center of Drum Tower Hospital, Clinical Cancer Institute of Nanjing University, Nanjing, People's Republic of China.Department of Geriatric Oncology, Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, People's Republic of China.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31571928

Citation

Li, Huiying, et al. "Treatment Response to Osimertinib in EGFR-Mutated Leptomeningeal Metastases From Non-Small Cell Lung Cancer: a Case Series." OncoTargets and Therapy, vol. 12, 2019, pp. 7785-7790.
Li H, Yu T, Huang M, et al. Treatment Response To Osimertinib In EGFR-Mutated Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Series. Onco Targets Ther. 2019;12:7785-7790.
Li, H., Yu, T., Huang, M., Guo, A., Qian, X., & Yin, Z. (2019). Treatment Response To Osimertinib In EGFR-Mutated Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Series. OncoTargets and Therapy, 12, 7785-7790. https://doi.org/10.2147/OTT.S199452
Li H, et al. Treatment Response to Osimertinib in EGFR-Mutated Leptomeningeal Metastases From Non-Small Cell Lung Cancer: a Case Series. Onco Targets Ther. 2019;12:7785-7790. PubMed PMID: 31571928.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment Response To Osimertinib In EGFR-Mutated Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Series. AU - Li,Huiying, AU - Yu,Tingting, AU - Huang,Mingmin, AU - Guo,Aibin, AU - Qian,Xiaoping, AU - Yin,Zhenyu, Y1 - 2019/09/20/ PY - 2018/12/25/received PY - 2019/09/10/accepted PY - 2019/10/2/entrez PY - 2019/10/2/pubmed PY - 2019/10/2/medline KW - EGFR mutation KW - T790M KW - leptomeningeal metastases KW - non-small cell lung cancer KW - osimertinib SP - 7785 EP - 7790 JF - OncoTargets and therapy JO - Onco Targets Ther VL - 12 N2 - Therapy for leptomeningeal metastases (LM) from non-small cell lung cancer (NSCLC) is challenging, and conventional treatments have little impact on the disease course. We report three cases that were definitively diagnosed as LM from NSCLC with a mutation of epidermal growth factor receptor (EGFR) L858R. The systemic therapies of chemotherapy, local radiotherapy, and early generation tyrosine kinase inhibitors (TKIs) were implemented but ineffective. Three patients were treated with the third-generation TKI osimertinib at 80 mg daily, despite their different detection levels of T790M in the cerebrospinal fluid (CSF) and plasma, and achieved symptomatic remission, a decline of carcinoembryonic antigen (CEA) levels, and stable lesions. After the progression of LM, osimertinib at 160 mg daily further lengthened the quality of life and survival time of patients without any notable side effects during treatment. Recent related studies and our cases indicate that osimertinib has a positive effect on LM from EGFR-mutant NSCLC, regardless of T790M status. SN - 1178-6930 UR - https://www.unboundmedicine.com/medline/citation/31571928/Treatment_Response_To_Osimertinib_In_EGFR_Mutated_Leptomeningeal_Metastases_From_Non_Small_Cell_Lung_Cancer:_A_Case_Series_ L2 - https://dx.doi.org/10.2147/OTT.S199452 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.